Addressing the"obesity paradox"in sepsis represents a specific challenge within this mechanistic framework; dedicated research is needed to understand adiponectin's contribution (or lack thereof) to the observed survival differences in obese versus non-obese septic patients, potentially linking it to baseline inflammatory status, adipose tissue dysfunction, and differential isoform secretion. Here, ADIPOQ is linked to Sepsis.